Open main menu

Transgender hormone therapy, also sometimes called cross-sex hormone therapy, is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity. This form of hormone therapy is given as one of two types, based on whether the goal of treatment is feminization or masculinization:

Some intersex people may also undergo hormone therapy, either starting in childhood to confirm the sex they were assigned at birth, or later in order to align their sex with their gender identity. Non-binary or genderqueer people may also undergo hormone therapy in order to achieve a desired balance of sex hormones.[1]

RequirementsEdit

The formal requirements for hormone replacement therapy vary widely.

The Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People (SOC) require that the patient be referred by a mental health professional who has diagnosed the patient with persistent gender dysphoria. The Standards also require that the patient give informed consent, in other words, that they consent to the treatment after being fully informed of the risks involved.[2]

Some LGBT health organizations (notably Chicago's Howard Brown Health Center[3]) advocate for an informed consent model where the patient must only prove that they understand the risk[4] and consent to the procedure in order to access hormone therapy.

Some individuals choose to self-administer their medication ("do-it-yourself") because they do not have access to adequate medical care (either the available doctors do not have the necessary experience or the patient cannot afford care since transition-related procedures are prohibitively expensive and rarely covered by health insurance). However, self-administration of hormones is potentially dangerous. Individuals seeking physicians who are knowledgeable and willing to treat transgender patients may wish to consult transgender support groups or a directory of LGBT-friendly doctors.

Treatment OptionsEdit

GuidelinesEdit

The World Professional Association for Transgender Health (WPATH) and the Endocrine Society formulated guidelines that created a foundation for health care providers to care for trans-gendered patients .[5]

Feminizing Hormone TherapyEdit

Feminizing hormone therapy usually includes medication to suppress testosterone production and induce feminization. Types of medication include testosterone blockers, estrogen, and progesterone.[6] Most commonly, 100 to 200 milligrams of spironolactone (Aldactone) daily is used to decrease testosterone production. After six to eight weeks of spironolactone therapy, estrogen can be started to further suppress testosterone production and promote feminization.[7]

Masculinizing Hormone TherapyEdit

Masculinizing hormone therapy usually includes testosterone to suppress the production of estrogen.[8] Treatment options include oral, parental, implant (subcutaneous), and trans-dermal (patches, creams). Dosing is patient specific and is discussed with the physician.[9]

Treatment options for transgender Men [5]
Route Formulation Dosing
Oral Testosterone undecanoate 160–240 mg/day
Parental Testerone enanthate , cypionate 50– 200 mg/ week
Implant Testopel 75 mg/pellet
Transdermal Testosterone gel (1%)

Testosterone patch

2.5 - 10 g/day

2.5 -7.5 mg/day

SafetyEdit

Hormone therapy for transgender individuals has been shown in medical literature to be generally safe, when supervised by a qualified medical professional.[10] There are potential risks with hormone treatment that will be monitored through screenings and lab tests such as blood count, kidney and liver function, blood sugar, potassium and cholesterol.[9][6] Taking more hormone than directed can lead to serious health problems such as increased risk of cancer, heart attack from thickening of the blood, and elevated cholesterol.[9]

Fertility ConsiderationEdit

Transgender hormone therapy replacement may limit fertility potential.[11] Should a transgender individual choose to undergo sex reassignment surgery, their fertility potential is lost completely.[12] Before starting any treatment, individuals may consider fertility issues and fertility preservation. Options include semen cryopreservation, oocyte cryopreservation, and ovarian tissue cryopreservation.[11][12]

A study due to be presented at ENDO 2019 (the Endocrine Society's conference) reportedly shows that even after one year of treatment with the hormone testosterone, a transgender man can preserve his fertility potential.[13]

Treatment EligibilityEdit

Eligibility is determined using major diagnostic tools such as ICD-10 or the Diagnostic and Statistical Manual of Mental Disorders (DSM). Psychiatric conditions can commonly accompany or present similar to gender incongruence and gender dysphoria. For this reason, patients are assessed using DSM-5 criteria or ICD-10 criteria in addition to screening for psychiatric disorders. The Endocrine Society requires physicians that diagnose gender dysphoria and gender incongruence to be trained in psychiatric disorders with competency in ICD-10 and DSM-5 . The healthcare provider should also obtain a thorough assessment of the patient's mental health and identify potential psychosocial factors that can affect therapy.[14]

ICD-10Edit

The ICD-10 system requires that patients have a diagnosis of either transsexualism or gender identity disorder of childhood. The criteria for transsexualism include:[15]

  • A desire to live and be accepted as a member of the opposite sex, usually accompanied by a sense of discomfort with, or inappropriateness of, one's anatomic sex
  • A wish to have surgery and hormonal treatment to make one's body as congruent as possible with one's preferred sex

Individuals cannot be diagnosed with transsexualism if their symptoms are believed to be a result of another mental disorder, or of a genetic or chromosomal abnormality.[citation needed]

For a child to be diagnosed with gender identity disorder of childhood under ICD-10 criteria, they must be pre-pubescent and have intense and persistent distress about being the opposite sex. The distress must be present for at least six months. The child must either:

  • Have a preoccupation with stereotypical activities of the opposite sex – as shown by cross-dressing, simulating attire of the opposite sex, or an intense desire to join in the games and pastimes of the opposite sex – and reject stereotypical games and pastimes of the same sex, or
  • Have persistent denial relating to their anatomy. This can be shown through a belief that they will grow up to be the opposite sex, that their genitals are disgusting or will disappear, or that it would be better not to have their genitals.

DSMEdit

The DSM-5 states that at least two of the following criteria must be experienced for at least six months' duration for a diagnosis of gender dysphoria:[16]

  • A strong desire to be of a gender other than one's assigned gender
  • A strong desire to be treated as a gender other than one's assigned gender
  • A significant incongruence between one's experienced or expressed gender and one's sexual characteristics
  • A strong desire for the sexual characteristics of a gender other than one's assigned gender
  • A strong desire to be rid of one's sexual characteristics due to incongruence with one's experienced or expressed gender
  • A strong conviction that one has the typical reactions and feelings of a gender other than one's assigned gender

In addition, the condition must be associated with clinically significant distress or impairment.[16]

ReadinessEdit

Some organizations – but fewer than in the past – require that patients spend a certain period of time living in their desired gender role before starting hormone therapy. This period is sometimes called real-life experience (RLE). The Endocrine Society stated in 2009 that individuals should either have a documented three months of RLE or undergo psychotherapy for a period of time specified by their mental health provider, usually a minimum of three months.[17]

Transgender and gender non-conforming activists, such as Kate Bornstein, have asserted that RLE is psychologically harmful and is a form of "gatekeeping", effectively barring individuals from transitioning for as long as possible, if not permanently.[18]

AccessibilityEdit

Some transgender people choose to self-administer hormone replacement medications, often because doctors have too little experience in this area, or because no doctor is available. Others self-administer because their doctor will not prescribe hormones without a letter from a psychotherapist stating that the patient meets the diagnostic criteria and is making an informed decision to transition. Many therapists require at least three months of continuous psychotherapy and/or real-life experience before they will write such a letter. Because many individuals must pay for evaluation and care out-of-pocket, costs can be prohibitive.

Access to medication can be poor even where health care is provided free. In a patient survey conducted by the United Kingdom's National Health Service in 2008, 5% of respondents acknowledged resorting to self-medication, and 46% were dissatisfied with the amount of time it took to receive hormone therapy. The report concluded in part: "The NHS must provide a service that is easy to access so that vulnerable patients do not feel forced to turn to DIY remedies such as buying drugs online with all the risks that entails. Patients must be able to access professional help and advice so that they can make informed decisions about their care, whether they wish to take the NHS or private route without putting their health and indeed their lives in danger."[19] Self-administration of hormone replacement medications may have untoward health effects and risks.[20]

See alsoEdit

ReferencesEdit

  1. ^ Ferguson, Joshua M. (November 30, 2017). "What It Means to Transition When You're Non-Binary". Teen Vogue.
  2. ^ Coleman, Eli; et al. (August 2012). "Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7". International Journal of Transgenderism. 13 (4): 165–232. doi:10.1080/15532739.2011.700873.
  3. ^ Schreiber, Leslie. "Howard Brown Health Center Establishes Transgender Hormone Protocol". www.howardbrown.org. Howard Brown. Archived from the original on 2011-10-08. Retrieved 2011-08-25. Cite uses deprecated parameter |dead-url= (help)
  4. ^ "THInCing About Hormones?: Hormone FAQs" (PDF). Retrieved 2011-12-14.
  5. ^ a b Unger, Cécile A. (December 2016). "Hormone therapy for transgender patients". Translational Andrology and Urology. 5 (6): 877–884. doi:10.21037/tau.2016.09.04. ISSN 2223-4691. PMC 5182227. PMID 28078219.
  6. ^ a b "Information on Estrogen Hormone Therapy | Transgender Care". transcare.ucsf.edu. Retrieved 2019-08-07.
  7. ^ "Feminizing hormone therapy - Mayo Clinic". www.mayoclinic.org. Retrieved 2019-08-02.
  8. ^ "Masculinizing hormone therapy - Mayo Clinic". www.mayoclinic.org. Retrieved 2019-08-02.
  9. ^ a b c "Information on Testosterone Hormone Therapy | Transgender Care". transcare.ucsf.edu. Retrieved 2019-08-07.
  10. ^ "Weinand J, Safer J. Feb 2015. "Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals." Journal of Clinical & Translational Endocrinology (2015)".
  11. ^ a b TʼSjoen, Guy; Van Caenegem, Eva; Wierckx, Katrien (2013). "Transgenderism and reproduction". Current Opinion in Endocrinology, Diabetes, and Obesity. 20 (6): 575–579. doi:10.1097/01.med.0000436184.42554.b7. ISSN 1752-2978. PMID 24468761.
  12. ^ a b De Sutter, P. (2001). "Gender reassignment and assisted reproduction: present and future reproductive options for transsexual people". Human Reproduction (Oxford, England). 16 (4): 612–614. doi:10.1093/humrep/16.4.612. ISSN 0268-1161. PMID 11278204.
  13. ^ "Ovary function is preserved in transgender men at one year of testosterone therapy | Endocrine Society". www.endocrine.org. Retrieved 2019-03-25.
  14. ^ "CORRIGENDUM FOR "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline"". The Journal of Clinical Endocrinology & Metabolism. 103 (7): 2758–2759. 2018-07-01. doi:10.1210/jc.2018-01268. ISSN 0021-972X. PMID 29905821.
  15. ^ "ICD-10 Diagnostic Codes". ICD-10:Version 2010. Retrieved 2014-06-08.
  16. ^ a b American Psychiatry Association (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (5th ed.). Washington, DC and London: American Psychiatric Publishing. pp. 451–460. ISBN 978-0-89042-555-8.
  17. ^ Hembree, Wylie, C; Cohen-Kettenis, Peggy; Delemarre-van de Waal, Henriette; Gooren, Louis; Meyer III, Walter; Spack, Norman; Tangpricha, Vin; Montori, Victor (September 2009). "Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline" (PDF). Clinical Endocrinology & Metabolism. 94 (9): 3132–54. doi:10.1210/jc.2009-0345. PMID 19509099. Archived from the original (PDF) on 2016-03-11. Retrieved 2014-06-07. Cite uses deprecated parameter |dead-url= (help)
  18. ^ Bornstein, Kate (2013). My Gender Workbook, Updated : How to Become a Real Man, a Real Woman, the Real You, or Something Else Entirely (2nd ed.). New York: Routledge. ISBN 978-0415538657.
  19. ^ "Survey of Patient Satisfaction with Transgender Services" (PDF). Archived from the original (PDF) on 2016-03-04. Retrieved 2016-01-08. Cite uses deprecated parameter |dead-url= (help)
  20. ^ Becerra Fernández A, de Luis Román DA, Piédrola Maroto G (October 1999). "Morbilidad en pacientes transexuales con autotratamiento hormonal para cambio de sexo" [Morbidity in transsexual patients with cross-gender hormone self-treatment] (PDF). Med Clin (Barc) (in Spanish). 113 (13): 484–7. ISSN 0025-7753. PMID 10604171.